Fact-Check Summary
Multiple reputable sources confirm that Bristol Myers Squibb and Pfizer are launching a direct-to-consumer program for the blood thinner Eliquis, offering it to patients at a discounted price following discussions with the Trump administration. The program is set to begin September 8, 2025, targeting uninsured and underinsured patients. The new cash price is $346 for a 30-day supply, representing over 40% off the $606 list price. This factual information matches the original social media post and reflects current events accurately.
Belief Alignment Analysis
The initiative supports increased access for patients who may otherwise struggle to afford Eliquis, aligning with democratic values of fairness and inclusivity. However, the discount program’s limitations—the price remains higher than what Medicare and international purchasers pay—highlight enduring systemic imbalances in healthcare access. While the move was influenced by executive leadership, it leaves many still without truly affordable coverage, revealing persistent issues of power and economic disparity within the American system. For our vision of a fair and inclusive America, such efforts must be viewed as steps forward, but not substitutes for broader reforms.
Opinion
While the announcement of discounted Eliquis sales is welcome news for millions without drug coverage, the fact that American patients remain subject to prices far above those in other developed countries is unacceptable. This direct-to-consumer model indicates progress, yet it also reflects the pharmaceutical industry’s ongoing preference to make voluntary concessions rather than embrace deeper, systemic reform. True patriotism demands we push beyond piecemeal measures and demand a healthcare system that works fairly for everyone, not just the well-connected or those with the loudest voices in Washington.
TLDR
Bristol Myers Squibb and Pfizer’s plan to sell Eliquis directly to patients at a discounted price is accurate and set to launch in September 2025 after Trump administration talks. The program provides relief for uninsured and underinsured patients but is still not as affordable as prices offered through Medicare or overseas. This step, while positive, underscores the need for lasting, systemic drug pricing reform in the United States.
Claim: Bristol Myers Squibb and Pfizer are launching a discounted direct-to-consumer sales program for Eliquis after consultations with the Trump administration.
Fact: Verified. News reports confirm the program launches September 2025, offering a 43% discount for uninsured and underinsured patients and resulting from policy discussions with the Trump administration.
Opinion: While this initiative expands access to a life-saving drug, many Americans will still pay far more than their peers abroad or those covered under Medicare. Democratic values require broader, structural change to ensure equitable, affordable healthcare for all—voluntary company offerings, though helpful, are not enough.